Chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) in psoriasis.
Indian J Dermatol Venereol Leprol
;
2006 Mar-Apr; 72(2): 133-5
Article
in English
| IMSEAR
| ID: sea-51919
ABSTRACT
BACKGROUND:
Insights into the pathogenesis of psoriasis have provided opportunities to target key steps in the disease process. Tumor necrosis factor-alpha (TNF- alpha) being crucial to the pathogenesis of psoriasis, monoclonal antibodies against this cytokine have proved useful in its treatment.AIM:
To study the efficacy of chimeric monoclonal antibody to TNF- alpha (infliximab) in Indian patients with recalcitrant psoriasis vulgaris. MATERIALS ANDMETHODS:
Three patients with recalcitrant psoriasis vulgaris were studied. Baseline haemogram, biochemical parameters, chest radiograph and Mantoux skin test were performed. A loading dose regimen of 5 mg/kg infliximab was administered at weeks 0, 2 and 6. PASI assessment, adverse drug event monitoring and laboratory assessments were carried out at 2-week intervals until week 10. Patients were followed up until week 22 for relapse.RESULTS:
Infliximab was well tolerated. The mean PASI was 25.4 at presentation and declined to 5.5 at 10 weeks. PASI 75 was attained at a mean of 9.6 weeks. Relapse occurred at a mean of 18.6 weeks after the first infusion.CONCLUSIONS:
This study on Indian patients brings out the importance of cytokine-based therapies in psoriasis. Indigenous production could make these therapies a viable therapeutic option for psoriasis patients in the near future.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Psoriasis
/
Humans
/
Pilot Projects
/
Tumor Necrosis Factor-alpha
/
Middle Aged
/
Antibodies, Monoclonal
Language:
English
Journal:
Indian J Dermatol Venereol Leprol
Year:
2006
Type:
Article
Similar
MEDLINE
...
LILACS
LIS